AXNX News and Press, Axonics Modulation Technologies Inc. From 09/02/21

Axonics (NASDAQ: AXNX) specializes in making medical devices to treat bladder and bowel dysfunction. It's the type of therapy that may be embarrassing to some, but the company's financial performance is nothing to be ashamed of. On Monday, the stock hit its 52-week high of $74.4...

Axonics, Inc. (AXNX) Q2 2021 Earnings Conference Call August 5, 2021, 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Guggenheim Travis Steed - Barclays Ada...

Axonics Modulation Technologies (NASDAQ:AXNX): Q2 GAAP EPS of -$0.59 misses by $0.09. Revenue of $45.9M (+202.0% Y/Y) beats by $6.08M. As of June 30, 2021, cash and cash equivalents were $231.1 million. Press Release For further details see: Axonics Modulation Technologies EPS misses by...

Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million Bulkamid ® revenue of $5.7 million in first full quarter since acquisition Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million Ax...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the appointment of Esteban López, M.D., MBA, to its board of directors, effective immediately....

BioLife Solutions Announces Changes to Board of Directors Chairman of the Board Raymond W. Cohen Retires After 15 Years of Service CEO Mike Rice Elected Chairman PR Newswire BOTHELL, Wash. , July 14, 2021 /PRNewswire/ -- BioLife Solutions , ...

cagkansayin/iStock via Getty Images Barclays initiated the coverage of Axonics (AXNX) with an outperform recommendation citing the potential of the company to top the current consensus estimates. The price target of $74.00 per share indicates a premium of ~14.5% to the close. “We are b...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. In conju...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable ...

Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today